Results 251 to 260 of about 71,938 (313)

Strategy of cell therapy evaluation in GRMD dog (modelof Duchenne muscular dystrophy): quantitative proteomic analysis of skeletal muscle

open access: green, 2012
Laëtitia Guével   +9 more
openalex   +1 more source

DWORF expression is reduced in a large animal model of Duchenne muscular dystrophy.

open access: yesDis Model Mech
Gibson AM   +12 more
europepmc   +1 more source

Duchenne muscular dystrophy [PDF]

open access: yesNature Reviews Disease Primers, 2021
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads to difficulties with movement and, eventually, to the need for assisted ventilation and premature death. The disease is caused by mutations in DMD (encoding dystrophin) that abolish the production of dystrophin in muscle.
Dongsheng Duan   +2 more
exaly   +7 more sources

DUCHENNE'S MUSCULAR DYSTROPHY

Medical Journal of Australia, 1968
G. B. A. Duchenne's description of pseudohypertrophic muscular paralysis contains not only the first clear account of this disease, but also the first report of a practical instrument of muscle biopsy. Duchenne (1806-1875) was a French neurologist who was led to a careful study of neuromuscular diseases through his interest in the effects of ...
I A, Brody, R H, Wikins
openaire   +4 more sources

Duchenne muscular dystrophy

BMJ, 2020
### What you need to know Duchenne muscular dystrophy (DMD) is a progressive and disabling neuromuscular condition that is often diagnosed late.1 In the UK the mean age of diagnosis has remained fairly static over the past 30 years, currently around 4.3 years of age.2 On average it takes 1.6 years from first parental concern to diagnosis of DMD,2 by ...
Hannah, Fox   +3 more
openaire   +2 more sources

Duchenne muscular dystrophy

Current Treatment Options in Neurology, 2001
Duchenne muscular dystrophy (DMD) is not treatable; there is no cure. More than a decade ago, randomized trials demonstrated that oral steroid therapy was of benefit to DMD patients by prolonging ambulation. Although few significant side effects were reported, study patients were followed for 18 months or less. However, when treating DMD with steroids,
Susan T., Iannaccone, Zohair, Nanjiani
openaire   +2 more sources

Duchenne muscular dystrophy

Neurology India, 2008
AbstractDuchenne muscular dystrophy, an X‐linked disorder, has an incidence of one in 5000 boys and presents in early childhood with proximal muscle weakness. Untreated boys become wheelchair bound by the age of 12 years and die of cardiorespiratory complications in their late teens to early 20s.
Yiu, Eppie M., Kornberg, Andrew J.
openaire   +3 more sources

Duchenne muscular dystrophy

BMJ, 2010
I was diagnosed with Duchenne muscular dystrophy at the age of 3. My parents were always honest about my disease, but I didn’t really care much about it. As the progression was slow, I gradually began to understand its impact, including the physical restrictions. I’m now severely disabled and have lived much longer than the doctors expected.
Spies, Stefan   +3 more
openaire   +3 more sources

Biomarkers in Duchenne Muscular Dystrophy

Current Heart Failure Reports, 2022
This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD).Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD.
Theo, Lee-Gannon   +3 more
openaire   +2 more sources

Duchenne muscular dystrophy

1995
Duchenne and Becker muscular dystrophy are X-linked muscle-wasting disorders that arise from mutations in the gene coding for dystrophin. The incidence of Duchenne muscular dystrophy (DMD) is approximately 1 in 3500 live male births, one-third of which are sporadic with no previous family history. In the absence of dystrophin, patients with DMD exhibit
G, Dickson, S C, Brown
openaire   +2 more sources

Home - About - Disclaimer - Privacy